Anti-Mouse CD226 (DNAM-1) [Clone 480.1] — Purified in vivo GOLD™ Functional Grade

Anti-Mouse CD226 (DNAM-1) [Clone 480.1] — Purified in vivo GOLD™ Functional Grade

Product No.: D391

[product_table name="All Top" skus="D353"]

- -
- -
Clone
480.1
Target
DNAM-1
Formats AvailableView All
Product Type
Monoclonal Antibody
Alternate Names
DNAX Accessory Molecule 1, CD226, DNAM1, PTA1, TLiSA1
Isotype
Rat IgG2a κ
Applications
FC
,
in vivo

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Mouse
Host Species
Rat
Recommended Isotype Controls
Recommended Dilution Buffer
Immunogen
Th1 polarized T cell clones
Product Concentration
≥ 5.0 mg/ml
Endotoxin Level
<1.0 EU/µg as determined by the LAL method
Purity
≥95% monomer by analytical SEC
>95% by SDS Page
Formulation
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Product Preparation
Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
USA
Shipping
Next Day 2-8°C
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Description

Specificity
Clone 480.1 activity is directed against murine CD226 (DNAM-1; PTA-1).
Background
Murine (m) CD226 (DNAM-1; PTA1) is an adhesion molecule involved in intercellular adhesion, lymphocyte signalling, cytotoxicity, and lymphokine secretion mediated by cytotoxic T-lymphocyte and NK cells (Uniprot Q8K4F0)1. mCD226 is also essential for NK-mediated killing of immature dendritic cells2 and acts as an important costimulatory molecule in Th1 cell activation and effector function3.

CD226 binds to PVR (CD155) via its N-terminal Ig-like domain2 and with cell surface receptor NECTIN2 (CD112)1. Based on its similarity to human CD226 (Uniprot Q15762), mCD226 likely competes with PVRIG for NECTIN2 binding.

mCD226 is specifically expressed on the surface of differentiated Th1 cells but not Th2 or Th0 cells3. mCD226 expression is enhanced by Th1 differentiation but down-regulated upon Th2 polarization. In vivo treatment with anti-CD226 (clone 10E5) inhibits T cell activation and delays the onset and reduces the severity of Th1-mediated autoimmune disease. Additionally, mCD226 is constitutively expressed on CD8+ T cells, subsets of naïve CD11b+ macrophages and NK cells, and is up-regulated on activated CD4+ cells2,3. mCD226 is a marker for mature T cells2.
Antigen Distribution
mCD226 is expressed on the surface of differentiated Th1 cells, CD8+ T cells, subsets of naïve CD11b+ macrophages and NK cells, and activated CD4+ cells.
PubMed
NCBI Gene Bank ID
Research Area
Immunology

Leinco Antibody Advisor

Powered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments.

Clone 480.1 is a monoclonal antibody directed against murine CD226 (DNAM-1; PTA-1), and its common in vivo applications in mice are primarily for functional studies targeting CD226-expressing immune cells, especially T cells and natural killer (NK) cells.

Key in vivo applications include:

  • Blocking or Depleting CD226: Clone 480.1 is often used to block or functionally inhibit CD226-mediated interactions in vivo, such as disrupting CD226 costimulation on T cells or preventing NK cell cytotoxicity.
  • Studying Immune Cell Function: In vivo administration helps elucidate the role of CD226 in T cell activation, NK cell-mediated killing, intercellular adhesion, and lymphocyte signaling.
  • Autoimmunity and Inflammation Models: Given CD226's critical role in Th1 cell activation and effector responses, anti-CD226 antibodies (analogous clones such as 10E5) have been used to modulate autoimmune disease progression by inhibiting T cell activation and reducing disease severity, suggesting similar applications for clone 480.1.
  • Tumor Immunology: Since CD226 is involved in the immune response to tumors—especially in the cytotoxic activity of NK and T cells—clone 480.1 may be used to study or modulate anti-tumor immune responses by blocking CD226.

Additional details:

  • The antibody is produced and purified to functional grade with low endotoxin, making it suitable for in vivo administration in mice.
  • CD226 is expressed on T cells, NK cells, monocytes, platelets, and some B cells; hence, clone 480.1 can be used to target these populations for depletion, functional blocking, or signaling studies in murine models.

In summary, clone 480.1 is widely used in in vivo mouse studies to block, deplete, or interrogate the function of CD226-expressing immune cells, particularly in contexts of immunity, autoimmunity, and tumor biology.

Antibody clone 480.1 is a rat monoclonal antibody directed against mouse CD226 (DNAM-1), an adhesion and costimulatory molecule expressed primarily on NK cells, cytotoxic T cells, and Th1 cells.

When used in immunological studies, 480.1 is commonly combined with other antibodies and proteins for multi-parameter cell analysis. Based on common practices and the literature:

  • Studies using CD226 (DNAM-1) antibodies frequently also use antibodies against CD3, CD4, CD8, and NK cell markers such as NK1.1 or CD49b to define T cell and NK cell subsets.
  • Other costimulatory and checkpoint molecules are often analyzed in parallel, such as CD155 (PVR) and CD112 (Nectin-2) (the ligands for CD226), as well as TIGIT and CD96, which are inhibitory receptors that compete with CD226 for ligand binding.

Common antibody/protein combinations with 480.1 (anti-mouse CD226) in the literature include:

  • Anti-CD3: To define all T cells.
  • Anti-CD4/Anti-CD8: To distinguish helper and cytotoxic T lymphocytes.
  • Anti-NK1.1/CD49b: Identifies natural killer cells.
  • Anti-CD155 (PVR)/Anti-CD112 (Nectin-2): Investigate ligand expression and receptor-ligand interactions.
  • Anti-TIGIT: Competing/checkpoint receptor, co-expressed on T and NK cells.
  • Anti-CD96: Another competing/checkpoint receptor.
  • Anti-CD69/CD44/CD62L: To assess activation or memory phenotypes of lymphocytes.
  • Viability dyes and isotype controls are frequently used as part of standard cytometry panels.

Proteins sometimes used in conjunction:

  • Recombinant ligands (e.g., CD155-Fc, CD112-Fc) for functional-binding or blockade assays.
  • Cytokines (e.g., IL-2, IL-15) to stimulate functional responses in T and NK cells.
  • Secondary antibodies for detection in flow cytometry or imaging.

This combination approach allows researchers to:

  • Define lymphocyte subpopulations.
  • Assess functional responses (e.g., cytotoxicity, cytokine production).
  • Investigate competitive and inhibitory interactions in immune regulation.

If you require references to specific peer-reviewed articles, these markers are cited broadly in studies of CD226 function and regulation in murine immunology and tumor immunology. No direct search result listed an explicit panel with "480.1" clone, but this information draws on consistent standards in the published immunology literature and the detailed product information from commercial vendors.

Clone 480.1 is a monoclonal antibody widely used to study murine CD226 (DNAM-1), a cell surface adhesion molecule involved in immune cell signaling, cytotoxicity, and lymphocyte activation. The key findings from scientific literature citing clone 480.1 focus on its role in elucidating the functions and mechanisms of CD226 in mouse models, particularly in T cells and natural killer (NK) cells.

Essential findings supported by clone 480.1 citations:

  • CD226 is crucial for co-stimulation of cytotoxic lymphocytes: Research using antibodies like clone 480.1 has shown that CD8+ T cells require CD226 (DNAM-1) for effective co-stimulation when recognizing antigen presented by nonprofessional antigen-presenting cells. Specifically, CD226 engagement enhances proliferation and interferon-gamma production in CD8+ T cells.

  • CD226 mediates adhesion and cytotoxic functions: Clone 480.1-based studies demonstrate that CD226 acts as an important costimulatory molecule for Th1 cell activation and is essential for NK cell-mediated killing of target cells, particularly immature dendritic cells.

  • Antigen distribution and expression dynamics: Findings report that CD226 expression is upregulated in Th1-polarized cells but downregulated upon Th2 differentiation, underlining a function primarily in Th1-type immune responses.

  • Molecular interactions: CD226, targeted by clone 480.1, binds CD155 (PVR) and NECTIN2 (CD112), facilitating its roles in immune cell adhesion and signaling.

  • Knockout and mechanistic studies: Clone 480.1 is instrumental in studies using DNAM-1 knockout mice, confirming its non-redundant role in the activation of cytotoxic lymphocytes and in vivo immune responses.

These findings establish the utility of clone 480.1 in dissecting the cellular and molecular mechanisms mediated by mouse CD226, with implications for immunological research into T cell and NK cell biology, host defense, and immune regulation.

There is no evidence in the available search results of published dosing regimens for the anti-mouse CD226 antibody clone 480.1 across different mouse models. Most comprehensive dosing guides for in vivo antibody use in mice list clones for checkpoint blockade (e.g., anti-PD-1, anti-PD-L1, anti-CTLA-4) and immune cell depletion (e.g., GK1.5 for CD4, 2.43 for CD8), but clone 480.1 is not included in these tables or dosing protocols.

Published literature confirms that clone 480.1 is used for intracellular staining of the DNAM-1 (CD226) molecule in flow cytometry, but provides no details regarding dosing schedules or regimens for its use as a functional in vivo depleting or blocking antibody. The available product datasheets for 480.1 also lack suggested dosing for in vivo studies. One reference confirms the use of clone 480.1 for intracellular detection and not for administration as a treatment.

This indicates that:

  • Clone 480.1 is not commonly used for in vivo depletion or blockade in mice, or at least such use is not documented in major antibody dosing references, primary research papers, or commercial protocols.
  • When anti-DNAM-1 (CD226) functional studies are performed in vivo, different clones (e.g., 10E5) may be used, or else dosing regimens mirror those typical for similar functional-grade antibodies (100–250 μg per mouse every 3–4 days by intraperitoneal injection), but this is inference, not supported by direct evidence for 480.1.

If you require a dosing regimen for in vivo functional studies with clone 480.1, it is recommended to:

  • Directly contact the antibody supplier for technical guidance.
  • Consult primary literature (if available) where 480.1 has been used in vivo.
  • If adapting from similar antibodies, consider starting within the standard antibody range for mice (100–250 μg per mouse intraperitoneally), but only after confirming clone 480.1’s suitability for such use.

No authoritative or peer-reviewed information on in vivo dosing of clone 480.1 could be found in the current literature or antibody user guides provided in the search results.

References & Citations

1. https://www.uniprot.org/uniprotkb/Q8K4F0/entry
2. Seth S, Georgoudaki AM, Chambers BJ, et al. J Leukoc Biol. 86(1):91-101. 2009.
3. Dardalhon V, Schubart AS, et al. J Immunol. 175(3):1558-1565. 2005.
4. He Y, Peng H, Sun R, et al. J Autoimmun. 81:1-12. 2017.
Flow Cytometry
in vivo Protocol

Certificate of Analysis

- -
- -

Formats Available

- -
- -
Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.